Blue Sail Medical has released its 2026 half-year performance forecast, expecting to achieve a net profit attributable to shareholders of 90 million to 110 million yuan for the first half, reversing a loss from the same period last year. All of the company's business divisions were profitable in the first half, with total attributable net profit reaching approximately 250 million yuan. However, at the headquarters level, the company bore around 50 million yuan in repurchase interest for the Series A financing of its cardiovascular and cerebrovascular division, approximately 24 million yuan in interest on matured Blue Sail convertible bonds, as well as foreign exchange losses and other expenses, resulting in a combined negative impact on attributable net profit of about 150 million yuan.
Blue Sail Medical Co LtdCompany expects net profit of 90-110 million yuan for H1, reversing a year-ago loss.